OTIPRIO® (ciprofloxacin otic suspension)

OTIPRIO is a physician administered, single dose formulation of ciprofloxacin in development for the treatment of patients with acute otitis externa, also known as swimmer’s ear, and patients with acute otitis media with tympanostomy tubes.

Acute Otitis Externa (AOE) Program

In January 2017, we announced positive results from a pivotal Phase 3 clinical trial that evaluated a single administration of 12 mg OTIPRIO (equal to 0.2 mL) vs. sham (no treatment) in 262 pediatric and adult patients with AOE. In this trial, OTIPRIO met the primary endpoint by showing a statistically significant increase in clinical cure rate compared to sham at Day 8 (p<0.001) where clinical cure was defined as complete resolution of the signs and symptoms related to AOE. OTIPRIO also demonstrated a statistically significant superiority to sham in clinical cure rate at all other time points assessed including Day 4 (p=<0.021), Day 15 (p<0.001) and Day 29 (p<0.001), and was well-tolerated. Based on these positive results, we expect to submit a supplemental New Drug Application (sNDA) with the FDA in the first half of 2017.

Acute Otitis Media with Tympanostomy Tubes (AOMT) Program

We have successfully completed a Phase 2 trial of OTIPRIO in pediatric patients with AOMT. This trial demonstrated that both OTIPRIO doses, 6 mg (0.1 mL) and 12 mg (0.2 mL), were well-tolerated and achieved higher and statistically significant (p<0.05) clinical cure rates over sham (no treatment). We believe this trial supports the advancement of OTIPRIO into Phase 3 in AOMT and intend to discuss the requirements for such a program with the FDA in the first half of 2017.